툴젠

199800KOSDAQ

40.0 / 100

Reference Date: 2026-10-23

Financial Score14.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Toolgen specializes in gene-editing R&D, patent monetization, and the development of therapeutics and functional seeds using CRISPR/Cas9 and other technologies. As the world's only company to develop three types of gene-editing tools (ZFN, TALEN, CRISPR/Cas9), it leads in therapeutic drug development (e.g., TGT-001, TG-wAMD) and functional crop seed innovation (e.g., high-oleic soybeans, disease-resistant potatoes).

Number of Employees

66people

Average Salary

72.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

5.01Industry Average 1.200.0Point

4.2x industry avg (risky)

ROE

-64.34Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

2.89Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼17.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -44.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 28,650Won52-week high 138,20052-week low 28,650

1-month return1.0Point

1m -11.44% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
Neutral주식등의대량보유상황보고서(일반)2026-10-02